Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements.